burosumab · Medicine question

What evidence of bone disease is required for burosumab to be indicated in children and adolescents aged 1–17 years with X-linked hypophosphataemia?

Name: What evidence of bone disease is required for burosumab to be indicated in children and adolescents aged 1–17 years with X-linked hypophosphataemia?
Published: 2026-11-08T13:40:25.834Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

Burosumab is indicated for children and adolescents aged 1–17 years with X-linked hypophosphataemia who have radiographic evidence of bone disease.

Sources for this answer

Crysvita solution for subcutaneous injectionKyowa Kirin Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 13Document updated 15 April 2026

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about burosumab